Correction: Onodera et al. Prognostic Factors and Talaporfin Sodium Concentration in Photodynamic Therapy for Recurrent Grade 4 Glioma. Pharmaceuticals 2025, 18, 583
Error in Table
2.5. Analysis of Clinical Factors in the High vs. Low Intratumoral TS Concentration Groups
Newly Diagnosed | Recurrence | |||||||
---|---|---|---|---|---|---|---|---|
Hazard Ratio (95% CI) | p-Value | Hazard Ratio (95% CI) | p-Value | Hazard Ratio (95% CI) | p-Value | Hazard Ratio (95% CI) | p-Value | |
Age | 1.02 (0.99–1.04) | 0.26 | 1.02 (0.99–1.05) | 0.27 | 1.01 (0.99–1.03) | 0.22 | 2.03 (0.81–5.93) | 0.50 |
Male vs. female sex | 1.35 (0.62–2.94) | 0.44 | 1.08 (0.62–1.88) | 0.45 | ||||
KPS | 0.98 (0.95–1.00) | 0.097 | 0.96 (0.93–0.99) | 0.01 | 0.09 (0.02–0.33) | 0.0003 | 0.96 (0.95–0.99) | 0.0008 |
Alb | 1.51 (0.51–4.48) | 0.45 | 3.68 (1.05–13.76) | 0.047 | 2.22 (0.88–5.84) | 0.090 | 2.13 (0.81–5.93) | 0.13 |
Total cholesterol | 1.00 (0.98–1.01) | 0.59 | 1.00 (0.99–1.01) | 0.40 | ||||
Benzodiazepine | 2.36 (0.81–6.88) | 0.15 | 3.06 (0.96–9.76) | 0.059 | 0.77 (0.34–1.72) | 0.52 | 0.77 (0.34–1.74) | 0.52 |
Smoking | 1.57 (0.70–3.53) | 0.29 | 1.58 (0.67–3.73) | 0.3 | 1.07 (0.64–1.79) | 0.80 | 1.21 (0.67–2.19) | 0.53 |
Localization | ||||||||
Temporal vs. not temporal | 0.50 (0.22–1.11) | 0.079 | 1.00 (0.56–1.78) | 0.99 | ||||
Frontal vs. not frontal | 1.14 (0.51–2.56) | 0.75 | 0.72 (0.43–1.20) | 0.20 | ||||
Parietal vs. not parietal | 1.32 (0.53–3.31) | 0.56 | 1.36 (0.72–2.53) | 0.35 |
Newly Diagnosed | Recurrence | |||||
---|---|---|---|---|---|---|
Mean TS Concentration ≤0.16333 | Mean TS Concentration >0.16333 | Mean TS Concentration ≤0.0883 | Mean TS Concentration >0.0883 | |||
n = 21 51.2 (%) | n = 20 48.8 (%) | p-Value | n = 21 51.2 (%) | n = 20 48.8 (%) | p-Value | |
Male vs. female | 13 (31.7%)/8 (19.5%) | 13 (31.7%)/7 (17.1%) | 0.837 | 13 (31.7%)/8 (19.5%) | 14 (34.2%)/6 (14.6%) | 0.5843 |
Age, mean ± SD | 60.7 ± 12.2 | 61.3 ± 11.9 | 0.884 | 47.6 ± 14.2 | 53.6 ± 10.5 | 0.5843 |
Left vs. right (excluded bilateral case) | 11 (31.4%)/7 (20.0%) | 6 (17.1%)/11 (31.4%) | 0.1245 | 10 (26.3%)/9 (23.7%) | 6 (15.8%)/13 (34.2%) | 0.1869 |
Pathological diagnosis | ||||||
Mean MIB-1 ± SD | 28.9 ± 11.9 | 22.1 ± 11.5 | 0.0607 | 21.3 ± 15.4 | 22.0 ± 15.5 | 0.8886 |
ATRX intact vs. loss | 20 (51.2%)/0 (0%) | 18 (46.2%)/1 (2.6%) | 0.226 | 12 (30.8%)/7 (18.0%) | 16 (39.0%)/4 (9.7%) | 0.2407 |
P53 (+) vs. (−) | 4 (9.76%)/17 (41.5%) | 6 (14.6%)/14 (34.2%) | 0.4134 | 6 (15.0%)/14 (35.0%) | 7 (17.0%)/13 (31.7%) | 0.7356 |
IDH (+) vs. (−) | 0 (0%)/21 (51.2%) | 1 (2.4%)/19 (46.3%) | 0.226 | 5 (12.5%)/15 (37.5%) | 4 (9.7%)/16 (39.0%) | 0.7047 |
Part | ||||||
Temporal vs. not temporal | 7 (17.1%)/14 (34.2%) | 9 (22.0%)/11 (26.8%) | 0.4435 | 8 (19.5%)/13 (31.7%) | 5 (12.2%)/15 (36.6%) | 0.366 |
Frontal vs. not frontal | 11 (26.8%)/10 (24.4%) | 8 (19.5%)/12 (29.3%) | 0.4261 | 7 (17.1%)/14 (34.2%) | 8 (19.5%)/12 (29.3%) | 0.6577 |
Parietal vs. not parietal | 2 (4.9%)/19 (46.3%) | 2 (4.9%)/18 (43.9%) | 0.959 | 5 (12.2%)/16 (39.0%) | 5 (12.2%)/15 (36.6%) | 0.9293 |
Reference
- Onodera, M.; Kitahara, S.; Sato, Y.; Kawamata, T.; Muragaki, Y.; Masamune, K. Prognostic Factors and Talaporfin Sodium Concentration in Photodynamic Therapy for Recurrent Grade 4 Glioma. Pharmaceuticals 2025, 18, 583. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Onodera, M.; Kitahara, S.; Sato, Y.; Kawamata, T.; Muragaki, Y.; Masamune, K. Correction: Onodera et al. Prognostic Factors and Talaporfin Sodium Concentration in Photodynamic Therapy for Recurrent Grade 4 Glioma. Pharmaceuticals 2025, 18, 583. Pharmaceuticals 2025, 18, 1586. https://doi.org/10.3390/ph18101586
Onodera M, Kitahara S, Sato Y, Kawamata T, Muragaki Y, Masamune K. Correction: Onodera et al. Prognostic Factors and Talaporfin Sodium Concentration in Photodynamic Therapy for Recurrent Grade 4 Glioma. Pharmaceuticals 2025, 18, 583. Pharmaceuticals. 2025; 18(10):1586. https://doi.org/10.3390/ph18101586
Chicago/Turabian StyleOnodera, Mikoto, Shuji Kitahara, Yasuto Sato, Takakazu Kawamata, Yoshihiro Muragaki, and Ken Masamune. 2025. "Correction: Onodera et al. Prognostic Factors and Talaporfin Sodium Concentration in Photodynamic Therapy for Recurrent Grade 4 Glioma. Pharmaceuticals 2025, 18, 583" Pharmaceuticals 18, no. 10: 1586. https://doi.org/10.3390/ph18101586
APA StyleOnodera, M., Kitahara, S., Sato, Y., Kawamata, T., Muragaki, Y., & Masamune, K. (2025). Correction: Onodera et al. Prognostic Factors and Talaporfin Sodium Concentration in Photodynamic Therapy for Recurrent Grade 4 Glioma. Pharmaceuticals 2025, 18, 583. Pharmaceuticals, 18(10), 1586. https://doi.org/10.3390/ph18101586